For the quarter ending 2025-09-30, APLS made $458,578K in revenue. $215,884K in net income. Net profit margin of 47.08%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 458,578 | 178,494 | 166,797 | 212,527 |
| Cost of sales | 24,531 | 13,626 | 34,360 | 40,857 |
| Research and development | 68,186 | 67,015 | 86,420 | 76,353 |
| Selling, general and administrative | 142,678 | 131,139 | 129,345 | 121,483 |
| Total operating expenses | 235,395 | 211,780 | 250,125 | 238,693 |
| Net operating loss | 223,183 | -33,286 | -83,328 | -26,166 |
| Loss on extinguishment of development liability | - | - | - | 0 |
| Interest income | 4,376 | 2,607 | 2,658 | 3,397 |
| Interest expense | 11,279 | 11,152 | 11,049 | 6,967 |
| Other income/(expense), net | 37 | 146 | -165 | -1,765 |
| Net loss before taxes | 216,317 | -41,685 | -91,884 | -36,067 |
| Income tax expense | 602 | 466 | 341 | 286 |
| Net income/(loss) | 215,715 | -42,151 | -92,225 | -36,353 |
| Unrealized (loss)/gain on pension plans | - | - | - | 591 |
| Unrealized gain on pension benefits | -137 | - | - | - |
| Foreign currency translation | 32 | 485 | 254 | -759 |
| Total other comprehensive income | 169 | 485 | 254 | -168 |
| Comprehensive loss, net of tax | 215,884 | -41,666 | -91,971 | -36,521 |
| Net loss per common share, basic | 1.71 | -0.33 | -0.74 | -0.3 |
| Net loss per common share, diluted | 1.67 | -0.33 | -0.74 | -0.3 |
| Weighted-average number of common shares used in net loss per common share, basic | 126,424,000 | 126,024,000 | 125,453,000 | -124,355,957 |
| Weighted-average number of common shares used in net loss per common share, diluted | 130,067,000 | 126,024,000 | 125,453,000 | -124,355,957 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)